Core Insights - Avricore Health Inc. is expanding its HealthTab™ platform across North East London, adding 70 community pharmacy sites, building on successful NHS-linked cardiovascular programs with Barts Health NHS Trust [1][2] Company Strategy - The deployment reflects strong pharmacy engagement and increasing clinical demand, aligning with NHS priorities to shift care from hospitals to community settings [2][4] - Avricore's strategic focus on the UK demonstrates the scalability of HealthTab™ within complex NHS environments, positioning it for further growth in preventive and treatment-linked care pathways across England [4] HealthTab™ Platform - HealthTab™ is a comprehensive solution for community-based point-of-care testing (POCT) networks, integrating instruments, cloud software, standardized workflows, and training [5] - The platform ensures quality-assured testing and real-time analytics for public health reporting, reducing implementation complexity for participating sites [6] Quality Assurance - HealthTab™ meets high standards of analytical performance through a partnership with CEQAL Inc., ensuring a comprehensive quality management program [7] - The program includes centralized monitoring of reagents, internal quality-control procedures, and regular external quality-assessment events to support accuracy and consistency [8] Company Overview - Avricore Health Inc. focuses on acquiring and developing early-stage technologies to advance pharmacy practice and patient care, aiming to create the largest network of rapid testing devices in community pharmacies [9]

Company Overview - Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care [5] - The company's flagship offering, HealthTab™, aims to create the world's largest network of rapid testing devices in community pharmacies [5] Stock Options Announcement - The board of directors of Avricore has approved the granting of stock options for a total of 4,100,000 common shares at an exercise price of CAD $0.05 per share [1] - The options will vest quarterly starting from the date of grant and will expire 5 years from the grant date, contingent on the optionees remaining in their roles [2] HealthTab™ Product Details - HealthTab™ is a point-of-care testing solution that provides lab-accurate results from just a few drops of blood, with real-time data reporting [3] - The test menu includes up to 23 key biomarkers for chronic disease management, including diabetes and heart disease, and has recently added capabilities for bacterial and viral tests [3] HealthTab™ Network Model - The HealthTab™ network model enhances the role of pharmacists in primary care delivery and empowers patients to take control of their health [4] - It aims to reduce costs and waiting times while providing multiple revenue streams, including equipment leasing, direct access testing, and decentralized clinical trials [4]

Company Overview - Avricore Health Inc. has appointed Rodger Seccombe as the new CEO, who previously served as the Chief Technology Officer and is the President and Co-Founder of HealthTab™ Inc. [1][2] - The company is focused on acquiring and developing early-stage technologies to advance pharmacy practice and patient care, with its flagship offering being the HealthTab™ platform [5]. HealthTab™ Platform - HealthTab™ is a point-of-care testing solution that provides lab-accurate results from just a few drops of blood, reporting data in real time and covering up to 23 key biomarkers for chronic disease management [3]. - The platform has recently expanded its testing capabilities to include bacterial and viral tests, such as strep and COVID-19 [3]. Business Model and Market Position - The HealthTab™ network model enhances the role of pharmacists in primary care, empowering patients and reducing costs and waiting times [4]. - The model offers multiple revenue streams, including equipment leasing, direct access testing, disease management programs, and integration with third-party applications [4]. Leadership Transition - Hector Bremner has resigned as CEO and director, having played a significant role in the company's growth and UK expansion [2]. - The board expresses gratitude for Bremner's contributions and looks forward to future collaborations [2].

Core Insights - Avricore Health Inc. is expanding its HealthTab™ platform in the UK, emphasizing the role of pharmacists in chronic disease prevention and management [1][2] - The UK government is significantly investing in community pharmacies, with £645 million (approx. CAD $1.2 billion) pledged in 2024 and £617 million (approx. CAD $1.144 billion) in 2025 to enhance pharmacy-led services [5] - The company has concluded operations in Shoppers Drug Mart locations in Canada as of March 31, 2025, allowing for the redeployment of devices in Canada and the UK [3][4] Financial Performance - In 2024, total revenue increased by 37% year over year to $4,785,711, while gross profit rose by 56% to $1,880,306 [11] - The company reported a loss from operations of $668,977 in 2024, an improvement from a loss of $701,215 in 2023 [8] - Total assets decreased to $2,298,544 in 2024 from $2,538,205 in 2023, while total current liabilities dropped to $330,817 from $529,218 [8] HealthTab™ Expansion - The HealthTab™ platform launched in North East London in November 2024, targeting areas with high cardiovascular disease burdens [13] - The initiative is supported by local health authorities and aims to integrate with NHS digital systems to modernize care pathways [13][14] - The platform has already conducted over 930,000 blood pressure screenings in 6,000 pharmacies, demonstrating strong uptake [14][6] Future Strategy - The company plans to expand HealthTab™ into other major population centers in the UK, focusing on diverse demographics suitable for preventative health programs [15] - Following initial successes, the company aims to work with NHS stakeholders for broader adoption of HealthTab™, potentially integrating cholesterol testing into the Pharmacy First protocol [16] - Momentum is expected to grow throughout 2025 as NHS plans for expanding point-of-care testing in community pharmacies become clearer [17] Market Context - The point-of-care testing market is projected to reach $93.21 billion USD by 2030, indicating significant growth potential for HealthTab™ [19] - The UK government’s investment in pharmacy-led services aligns with the increasing demand for accessible healthcare solutions amid rising chronic disease rates [5][6]

S-1 1 aimd_s1.htm FORM S-1 As filed with the Securities and Exchange Commission on December 8, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ________________________ AINOS, INC. (Exact name of registrant as specified in its charter) (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) CT Corporation System 1999 Bryan St., Suite ...